Prevalence Of Chronic Hypercapnia In Severe Chronic Obstructive Pulmonary Disease: Data From The HOmeVent Registry

Michael Dreher, Pierre-Charles Neuzeret, Wolfram Windisch, Dagmar Martens, Gerhard Hoheisel, Andreas Gröschel, Holger Woehrle, Thomas Fetsch, Andrea Graml, Thomas Köhnlein, Michael Dreher, Pierre-Charles Neuzeret, Wolfram Windisch, Dagmar Martens, Gerhard Hoheisel, Andreas Gröschel, Holger Woehrle, Thomas Fetsch, Andrea Graml, Thomas Köhnlein

Abstract

Background: Non-invasive ventilation (NIV) has been shown to improve survival and quality of life in COPD patients with chronic hypercapnic respiratory failure. However, the proportion of COPD patients with chronic hypercapnia is not yet known and clinical data enabling better identification of patients are scarce. The HOmeVent registry was initiated to determine the prevalence of chronic hypercapnia in COPD in an outpatient setting and to evaluate the predictors of hypercapnia.

Methods: HOmeVent is a multicenter, prospective, observational, non-interventional patient registry that includes COPD patients in GOLD stage 3 or 4. Eligible patients were identified and enrolled in an outpatient setting during routine clinic visits. Assessments included blood gas analyses, pulmonary function testing and quality of life assessment.

Results: Ten outpatient clinics in Germany enrolled 231 COPD patients in the registry (135 in GOLD stage 3 (58%) and 96 in GOLD stage 4 (42%)). Arterial carbon dioxide pressure (PaCO2) was ≥45 mmHg in 58 patients (25%); of these, 20 (9%) had PaCO2 ≥50 mmHg. The prevalence of hypercapnia at both cut-off values was numerically higher for patients in GOLD stage 4 versus 3. An increased body mass index, a decreased forced vital capacity and an increased bicarbonate level were significant independent predictors of hypercapnia. The proportion of patients who received NIV was 6% overall and 22% of those with hypercapnia.

Conclusion: A relevant proportion of COPD patients in GOLD stage 3 and 4 exhibits chronic hypercapnia and might, therefore, be candidates for long-term domiciliary NIV treatment.

Keywords: chronic obstructive pulmonary disease; hypercapnia; non-invasive ventilation; quality of life; registry.

Conflict of interest statement

MD has received speaking and advisor fees from Phillips, Weinmann, and Heinen und Löwenstein, during the conduct of the study. WW has received speaking fees and advisory fees from Weinmann, Vivisol, Heinen und Löwenstein, VitalAire (all in Germany) and from Philips-REspironics (USA) ; in addition, the Cologne study group has received open research grants from Weinmann, Vivisol, Heinen und Löwenstein and VitalAire (all in Germany), and from Philips-Respironics (USA). HW is a paid consultant to ResMed. TF is Chief Executive Officer at the Clinical Research Institute which was in charge of the HOmeVent registry. PCN, DM and A Graml are employees of ResMed. A Gröschel reports personal fees from ResMed, during the conduct of the study. TK and GH have no conflicts of interest to disclose beyond financial support for the HOmeVent registry. The authors report no other conflicts of interest in this work.

© 2019 Dreher et al.

Figures

Figure 1
Figure 1
Prevalence of hypercapnia overall (A), and by GOLD stage 3 (B) or 4 (C).
Figure 2
Figure 2
Distribution of patients by arterial carbon dioxide pressure (PaCO2). Light blue = normocapnia (PaCO2 <45 mmHg); Dark blue = hypercapnic (PaCO2 45 to <50 mmHg); Red & black = hypercapnic with an indication for non-invasive ventilation in Germany (red= PaCO2 ≥50 mmHg; black = PaCO2 ≥ 50 mmHg).

References

    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
    1. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090. doi:10.1016/S0140-6736(18)31694-5
    1. Joshi M, Joshi A, Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr Opin Pulm Med. 2012;18(2):97–103. doi:10.1097/MCP.0b013e32834fa84c
    1. Janson C, Marks G, Buist S, et al. The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013;42(6):1472–1483. doi:10.1183/09031936.00153712
    1. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(2 Suppl):5s–9s. doi:10.1378/chest.117.2_suppl.5S
    1. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817–822. doi:10.1056/NEJM199509283331301
    1. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med. 2012;185(2):152–159. doi:10.1164/rccm.201106-1094OC
    1. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis. BMJ. 2003;326(7382):185. doi:10.1136/bmj.326.7402.1329-b
    1. Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med. 1994;120(9):760–770. doi:10.7326/0003-4819-120-9-199405010-00008
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of COPD. January 2015. Available from: Accessed October30, 2018.
    1. Chu CM, Chan VL, Lin AW, Wong IW, Leung WS, Lai CK. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax. 2004;59(12):1020–1025. doi:10.1136/thx.2004.024307
    1. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014;2(9):698–705. doi:10.1016/S2213-2600(14)70153-5
    1. McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009;64(7):561–566. doi:10.1136/thx.2008.108274
    1. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177–2186. doi:10.1001/jama.2017.4451
    1. Lloyd-Owen SJ, Donaldson GC, Ambrosino N, et al. Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J. 2005;25(6):1025–1031. doi:10.1183/09031936.05.00066704
    1. Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M. German national guideline for treating chronic respiratory failure with invasive and non-invasive ventilation - revised edition 2017: part 1. Respiration. 2018;96(2):66–97. doi:10.1159/000488001
    1. Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M. German national guideline for treating chronic respiratory failure with invasive and non-invasive ventilation - revised edition 2017: part 2. Respiration. 2018;96(2):171–203. doi:10.1159/000488667
    1. Criee CP, Baur X, Berdel D, et al. Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German respiratory society and German society of occupational and environmental medicine. Pneumologie. 2015;69(3):147–164. doi:10.1055/s-0034-1391345
    1. EuroQol Research Foundation. EQ-5D. Available from: Accessed May 13, 2019.
    1. Windisch W, Freidel K, Schucher B, et al. The Severe Respiratory Insufficiency (SRI) Questionnaire: a specific measure of health-related quality of life in patients receiving home mechanical ventilation. J Clin Epidemiol. 2003;56(8):752–759. doi:10.1016/s0895-4356(03)00088-x
    1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
    1. Suh ES, Murphy PB, Hart N. Home mechanical ventilation for chronic obstructive pulmonary disease: what next after the HOT-HMV trial? Respirology. 2019. doi:10.1111/resp.13484
    1. Budweiser S, Jorres RA, Riedl T, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest. 2007;131(6):1650–1658. doi:10.1378/chest.06-2124
    1. Raveling T, Wijkstra P, Bladder G, Nieuwenhuis J, Duiverman M. Predictors of survival in severe COPD patients initiated on chronic NIV. Eur Respir J. 2016;48:PA2154.
    1. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
    1. Budweiser S, Jorres RA, Riedl T, Heinemann F, Pfeifer M. Base excess, a marker of chronic hypercapnic respiratory failure and predictor of survival in COPD. Eur Respir Rev. 2006;15:194–196. doi:10.1183/09059180.00010118
    1. Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc. 2008;5(2):218–225. doi:10.1513/pats.200708-122MG
    1. Masa JF, Pepin JL, Borel JC, Mokhlesi B, Murphy PB, Sanchez-Quiroga MA. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151). doi:10.1183/16000617.0097-2018
    1. Chen C, Jian W, Gao Y, Xie Y, Song Y, Zheng J. Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness. Int J Chron Obstruct Pulmon Dis. 2016;11:2519–2526. doi:10.2147/COPD.S110021
    1. Similowski T, Yan S, Gauthier AP, Macklem PT, Bellemare F. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med. 1991;325(13):917–923. doi:10.1056/NEJM199109263251304
    1. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, Green M, Moxham J. Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154(5):1310–1317. doi:10.1164/ajrccm.154.5.8912741
    1. Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;132(1):42–47. doi:10.1164/arrd.1985.132.1.42

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe